During the past three decades, the incidence of esophageal adenocarcinoma has been dramatically increasing in Western Europe and the United States, surpassing the incidence of esophageal squamous cell carcionoma. Barrett's esophagus is a premalignant condition of esophageal adenocarcinoma, the malignant progression may develop through the metaplasia-dysplasia- adenocarcinoma sequence. Barrett's esophagus occurs in about 10% of GERD patients. Only in a small number of people with Barrett's esophagus may develop esophageal cancer. Detection of early, curable stages of the cancer is still the most important, outcome rates of a developed adenocarcinoma are poor. The optimal therapeutic approach to the various stages of the progression process is still controversial, we learn even more about the real value of local endoscopic therapies. Patients undergoing surveillance programs have a better outcome, but these programs are unable to decrease mortality rates of esophageal adenocarcinoma. There is a strong need for the ideal biomarker wich would select a group of patients with an increased risk to develop adenocarcinoma.
|Translated title of the contribution||Barrett's esophagus|
|Number of pages||9|
|Publication status||Published - Dec 1 2004|
ASJC Scopus subject areas